Kornimate/medical-research-clean huggingface dataset:
the study aims to measure the metabolome in melanoma patients using nmr spectroscopy and gas chromatography and to analyse differences depending on the course of the disease.

Conditions: Melanoma of Skin

Summary: prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage. the biosamples are collected in the biobank dresden and used for the nmr and lc-ms analyses described here. it is planned to use the biosamples for further analyses.


Eligibility criteria:
inclusion criteria: * current or past history of melanoma * ongoing therapy or tumour aftercare at the skin cancer centre at dresden university hospital exclusion criteria: * refusal to participate in the study * lack of capacity to consent

Keywords: melanoma metabolomics nmr
trial of electrosurgical incision versus bougie dilation of symptomatic lower esophageal (schatzki's) rings

Conditions: Lower Esophageal Ring; Dysphagia

Summary: the primary objective of this study is to compare the efficacy of bougie dilation to electrosurgical incision of symptomatic schatzki's rings at one year follow-up in the presence of rabeprazole treatment. all patients will be followed for one year for recurrence and/or severity of dysphagia and will be placed on rabeprazole for that time period.

fifty consecutive patients referred for endoscopic evaluation at endoscopy labs at the university of utah health sciences center and the salt lake city va medical center for dysphagia will be enrolled in the study prior to endoscopy. if a schatzki's ring is found at endoscopy, the patient will be randomized to electrosurgical incision or standard bougie dilation. patients will be placed on rabeprazole for one year. follow-up on recurrence and/or severity of dysphagia will be analyzed at interim time periods (1,3,6, 9 12 months).

Eligibility criteria:
inclusion criteria: * between the ages of 18-80 with symptomatic schatzki's ring * no history of bleeding diathesis or other contraindication to bougie dilation or electrosurgical incision exclusion criteria: * contraindication to proton pump inhibitors * pregnancy * inability to provide informed consent * history of previous esophagogastric surgery * presence of esophageal peptic stricture, esophageal motility disorder or esophageal cancer that could otherwise account for dysphagia * nasopharyngeal lesion or nasal intubation intolerance causing inability to undergo esophageal motility testing and ambulatory ph monitoring

Keywords: lower esophageal ring dysphagia electrosurgical incision bougie dilation gerd
bright light therapy for individuals with dementia

Conditions: Dementia

Summary: many older adults with dementia living in long-term care facilities experience depression and agitation, which cause angst and personal suffering. prior to this research, evidence was inconclusive but indicated that bright light exposure may reduce depression and agitation in long-term care residents with dementia. the purpose of this study was to determine if the degree of improvement in depression and agitation scores over the course of eight weeks was significantly greater in persons with dementia receiving bright light exposure than in persons with dementia receiving placebo light exposure. sixty individuals participated in the study, with 30 in the bright light group and 30 in the low level light group.


Eligibility criteria:
inclusion criteria were age 60 or older; diagnosis of dementia; ophthalmology screening indicating that the individual was able to perceive light and did not have cataracts, glaucoma, macular degeneration, or retinal problems; able to sit up and keep eyes open; and not too restless to sit for 30 minutes. exclusion criteria were age 59 or younger; no diagnosis of dementia; presence of cataracts, glaucoma, macular degeneration, or retinal problems; unable to sit up and keep eyes open; and too restless to sit for 30 minutes.

Keywords: dementia depression agitation bright light
vegf in iris tissue in primary congenital glaucoma

Conditions: Iris

Summary: estimation of vascular endothelial growth factor (vegf) in iris tissue specimen in primary congenital glaucoma through immunohistochemistry.

combined trabeculotomy with mitomycin c will done in infants with primary congenital glaucoma with histopathological examination of the the peripheral iris tissue specimen and vascular endothelial growth factor (vegf) estimation in iris tissue specimen through immunohistochemistry. estimation of vascular endothelial growth factor (vegf) in iris tissue specimen taking from ocular trauma or congenital cataract used as control.

Eligibility criteria:
inclusion criteria: * primary congenital glaucoma exclusion criteria: * infants with history of previous surgery. * secondary glaucoma. * glaucoma associated with other congenital anomalies.
evaluation of bol-303242-x versus vehicle for the treatment of inflammation following cataract surgery

Conditions: Cataract; Inflammation

Summary: this clinical study is being conducted to identify the most effective drug concentration and dose frequency of bol-303242-x (mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.


Eligibility criteria:
inclusion criteria: * subjects must be at least 18 years of age on the date the informed consent form (icf) is signed and with the capacity to voluntarily provide consent. * subjects must be able to understand and provide written consent on the institutional review board (irb)/ethics committee (ec) approved icf and provide authorization as appropriate for local privacy regulations. * subjects who are candidates for cataract surgery. * subjects who are not of childbearing potential or female subjects who have a negative urine pregnancy test result at screening. * subjects must be able and willing to comply with all treatment and follow- up procedures. exclusion criteria: * subjects who have known hypersensitivity or contraindication to the study drug(s) or their components. * subjects who have a history or presence of chronic generalized systemic disease that the investigator feels might increase the risk to the subject or confound the result of the study. * subjects who have a severe/serious ocular condition, or any other unstable medical condition that, in the investigator's opinion, may preclude study treatment or follow-up.

Keywords: surgery
treatment of keratoconus with advanced corneal crosslinking

Conditions: Keratoconus

Summary: the purpose of this study was to determine whether mechanical compression of the cornea during corneal crosslinking for keratoconus using a sutured rigid contact lens can improve the optical outcomes of the treatment.

the study is designed as a prospective, open, randomized controlled trial involving patients aged 18-28 years of both genders with uni- or bilateral keratoconus planned for routine corneal crosslinking at the department of ophthalmology, umeå university hospital, umeå, sweden. the study involves 30+30 eyes with keratoconus, which are randomized to receive either conventional corneal crosslinking (n=30) using the dresden protocol or a modified treatment - corneal reshaping and crosslinking (n=30), where a rigid contact lens is sutured to the cornea during the treatment to flatten the corneal curvature and potentially improve the optical outcome after the treatment. patients are randomized utilizing a list of unique random numbers between 1 and 60. all patients are informed about the procedures before consenting to participate in the study. the study also involves 60 eyes of healthy age- and sex-matched control subjects. at baseline, before treatment, each eye is evaluated with autorefractometer measurement, best spectacle-corrected logmar visual acuity, pentacam scheimpflug photography, goldmann applanation tonometry and biomicroscopy. the corneal biomechanical characteristics are assessed with applanation resonance tonometry and the ocular response analyzer. the investigations are repeated at 1 month, 6 months, 2 years and 5 years after the treatment.

Eligibility criteria:
inclusion criteria: * patients planned for corneal crosslinking. * progressive keratoconus documented with scheimpflug photography using the pentacam scheimflug camera and/or repeated subjective refraction and keratometry. * a keratoconus diagnosis based on the amsler-krumeich grading and the "total deviation" kc quantification value from the "belin-ambrosio enhanced ectasia" measurements of the pentacam scheimpflug camera, and an altered red reflex and/or an irregular cornea seen as distortion of the keratometric mires. * minimum corneal thickness of 400 µm at the thinnest point after epithelial removal. * 18-28 years of age * no ocular abnormalities except keratoconus * no previous ocular surgery * no cognitive insufficiency interfering with the informed consent. exclusion criteria: * age under 18 or over 28 * any corneal abnormalities except keratoconus * previous ocular surgery * cognitive insufficiency.

Keywords: keratoconus corneal crosslinking corneal biomechanics corneal densitometry scheimpflug photography
effect of platelet rich plasma on outcome of narrow band uvb in treatment of vitiligo; clinical and histopathological study

Conditions: Management of Stable Vitiligo

Summary: for each patient, one side of body will be treated with nb-uvb alone while the other side will be treated with nb-uvb therapy in addition to intradermal injection of prp every 2 weeks. patients will be photographed at the first visit, in the middle and at the end of therapy. each patient will sign a written consent form to be included in the study and to be photographed.


Eligibility criteria:
inclusion criteria: patients with stable non segmental vitiligo. (absence of koebnerization, absence of new lesion and absence of widening of the existing lesions). patients have more than 15 years. - exclusion criteria: patients have active vitiligo (appearance of new lesion, history of koebnerization). pregnant and lactating women. history of keloid formation. anemia (hemoglobin level \<10gm/dl), thrombocytopenia (platelet count \<100,000 /µl), coagulopathies or patients on anticoagulant therapy and patients with iron deficiency. patients taking drugs that prolong bleeding time such as aspirin and vitamin e patients taking treatment of vitiligo in last 2 months
testing a community-friendly risk reduction intervention for injection drug users

Conditions: HIV; Opioid Dependence

Summary: to conduct a randomized clinical trial (rct) of a community-friendly behavioral intervention designed to reduce hiv risk behavior among injection drug users (idus) in drug treatment by comparing risk-behavior outcomes of four weekly intervention sessions with a time-and-attention-matched control condition.

this research study will test the effects of chrp, a community-friendly risk reduction intervention, which is based on the information-motivation-behavioral skills model of health behavior change (imb; fisher \& fisher, 1992), and, thus, is designed to enhance knowledge, motivation, and behavior skills for reducing drug- and sex-related hiv risk behaviors. outcomes assessed will include urine toxicology screens, self-reported hiv drug- and sex-related hiv risk behavior, hiv/aids knowledge, risk reduction motivation, and risk reduction behavioral skills. to measure the effects of chrp, the investigators are proposing a two-condition (standard of care plus the chrp intervention vs. standard of care plus a time-and-attention matched control condition) randomized design, balancing for participant gender. the investigators will assess participants at baseline, immediately post-intervention (i.e., at 4 weeks), and at 3-, 6-, and 12-month measurement points following the intervention. this assessment approach will allow the investigators to examine the trajectory of hiv risk reduction change including the decay or emergence of intervention effects.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * opioid-dependent and seeking methadone maintenance treatment * report drug- or sex-related hiv risk behavior in previous 6 months * able to read and understand the questionnaires, audio computer assisted self interview (acasi), and consent form * available for the full duration of the study with no anticipated circumstances impeding participation (e.g., jail term) * not actively suicidal, homicidal, or psychotic as assessed by trained research staff under the supervision of a licensed clinical psychologist exclusion criteria:

Keywords: methadone-maintenance hiv risk behavior injection drug use condom use health care participation opioid replacement therapy
evaluation of patients treated with hmg-coa reductase inhibitors to reach cholesterol target values

Conditions: Hypercholesterolaemia

Summary: this study is non-interventional study of patients who are treated with any hmgcoa reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in bosnia and herzegovina for at least 6 months. data collection for each patient will take place at a single visit. the investigators will complete case report form (crf) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.

non-interventional study to assess reaching of cholesterol target values in patients treated with hmg-coa reductase inhibitors in bosnia and herzegovina

Eligibility criteria:
inclusion criteria: * patients, treated with one hmg-coa reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least * all patients must sign informed consent form exclusion criteria: * patients who have not signed the informed consent form * patients with contraindication for the treatment with hmg-coa reductase inhibitors as per smpc approved in bosnia and herzegovina

Keywords: dyslipidemia statins total cholesterol low density lipoprotein (ldl) cholesterol high density lipoprotein (hdl) cholesterol
music effect on the self-injection, testing fear and pain

Conditions: Type 2 Diabetes Mellitus (T2DM); Insulin; Fear; Pain; Injection; Music Therapy

Summary: diabetes is a chronic and broad-spectrum metabolic disorder characterized by hyperglycemia that occurs due to relative or absolute insulin deficiency or "insulin resistance" developed against insulin action in peripheral tissues, affecting many organs and causing multisystem involvement. metabolic function continues to deteriorate after diagnosis, leading to worsening glycemic control and insulin therapy becoming necessary. however, patients may have difficulty adhering to insulin therapy. fears about injections are common in both adults and children and, as research shows, are a major reason why people with diabetes avoid taking insulin. addressing these fears is an important part of helping patients reduce their risk of diabetes-related complications. helping patients manage their replacement pain may help reduce the effects of needle fear in the future. there are a number of strategies that can ease the pain.the use of music in pain management has advantages such as being reliable, cheap, and having no side effects, as well as reducing postoperative pain reports. music distracts the individual from negative stimuli and allows them to focus on something they enjoy, thus reducing pain and anxiety. music therapy has also been shown to have sedative-protective effects and reduce stress hormone levels. listening to preferred music can distract and reduce the pain and negative emotions associated with an unpleasant experience.

research type: the research will be conducted as a randomized controlled experimental model. research universe and sample: the research sample will consist of patients diagnosed with type 2 diabetes hospitalized in a state hospital. the sample of the research is expected to consist of 100 volunteer type 2 diabetes patients who applied to the state hospital.

Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least one year * self-administering insulin injection * self-administering glucometer, insulin pen or insulin pump exclusion criteria: * poor mental health * having gestational diabetes mellitus or type 1 diabetes * no hearing problems

Keywords: type 2 diabetes mellitus insulin fear pain insulin injection music
antidepressant treatment in older adults with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the safety and effectiveness of citalopram (celexa) for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia.

older people with schizophrenia suffer from greater physical comorbidity, cognitive impairment, and medication side effects compared to their younger counterparts. unfortunately, little research is available to guide the treatment of subsyndromal depressive symptoms in older adults. this study will compare the antidepressant citalopram to placebo to determine the most effective treatment for reducing depressive symptoms in older patients with schizophrenia after patients have been on stable treatment with antipsychotic medication for at least 4 weeks, they are randomly assigned to receive antipsychotic medication plus either citalopram or placebo for 3 months. depressive symptoms and side effects are assessed weekly for the first month, biweekly for the second month, and again at the end of the third month. cognition, motor and daily functioning, quality of life, and medication adherence are assessed throughout the study.

Eligibility criteria:
inclusion criteria: * schizophrenia or schizoaffective disorder * ham-d score of 8 or above * antipsychotic medication treatment

Keywords: psychotic disorders
patients with heart failure with preserved ejection fraction adherence to asv therapy (pep asv)

Conditions: Sleep Disorder; Breathing-Related; Heart Failure

Summary: this is a prospective, single-arm, unblinded pilot study and registry that aims to demonstrate adherence to adaptive servo-ventilation (asv) therapy in patients with moderate to severe sleep disordered breathing who have been recently hospitalized. asv therapy has been linked to improved outcomes in this population, but adherence to therapy is low. the aircurve 10 asv device that will be used for this study employs newer technologies, such as web-based monitoring and provides patients feedback, which may increase therapy adherence and therefore improve patient outcomes.


Eligibility criteria:
inclusion criteria: * 1. patients 18 years or older 2. patients with heart failure with preserved ejection fraction (hfpef; lvef ≥50%) 3. hospital admission or equivalent (such as er visit alone or clinic visit alone) and acute decompensated hf as determined by: 1. dyspnea at rest or with minimal exertion and 2. treatment with at least one dose of iv diuretic or ultrafiltration and 3. at least two of the following signs and symptoms: i. orthopnea ii. pulmonary rales that do not clear with cough iii. congestion on chest x-ray iv. local bnp or nt pro-bnp level: * no current afib: bnp≥100 pg/ml or nt pro-bnp≥300 pg/ml or * current afib: bnp≥150 pg/ml or nt pro-bnp≥450 pg/ml 4. sleep disordered breathing (sdb) documented by screening polygraphy with an ahi≥15 events/hour (e/hr) 5. patient is able to fully understand study information and sign informed consent exclusion criteria: 1. right-sided heart failure without left-sided failure 2. current chronic use (within 4 weeks of registry entry) of any pap therapy (e.g., cpap, apap, or bi-level) or contraindicated for pap therapy 3. sustained systolic blood pressure \<80 mmhg at baseline 4. complex congenital heart disease 5. constrictive pericarditis 6. chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day or night) 7. transient ischemic attack (tia) or stroke within 3 months prior to registry entry 8. definite clinically evident acute myocardial infarction within 3 months of registry entry 9. known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas 10. moderate or greater valvular heart disease as the primary reason for heart failure 11. in the opinion of the investigator, the index acute decompensated hf event was not due primarily to uncontrolled afib with fast ventricular response rate 12. inability to comply with planned study procedures
clinical presentations and outcomes of patients with covid-19 pneumonia

Conditions: COVID-19 Pneumonia

Summary: this study aims at determining clinical presentations and outcomes of patients with covid-19 pneumonia and also follow up of patients for up to 6 months to detect possibility of post covid fibrosis

according to the world health organization (who), the emergence of viral diseases represents a serious public health risk. in the past two decades, several epidemics caused by viruses such as the severe acute respiratory syndrome coronavirus (sars-cov) from 2002 to 2003, and h1n1 influenza in 2009, and the middle east respiratory syndrome coronavirus (mers-cov) in 2012 have been described which have had a significant impact on global health. since being declared a global pandemic by the who, sars-cov-2, the virus responsible for covid-19 has spread to 223 countries with more than 178 million confirmed cases, and more than 3.8 million deaths reported worldwide. the u.s. experienced the highest number of sars-cov-2 infections and covid-19 related deaths followed by brazil and india. in fact, covid-19 was the third leading cause of death in the u.s. in 2020 after heart disease and cancer, with approximately 375,000 death reported . as of 22 june 2021, the alpha(b.1.1.7) variant has spread to 170 countries, the beta (b.1.351) variant has been reported in 119 countries, the gamma (p.1) variant has been detected in 71 countries and the delta variant(b.1.617.2) has spread to 85 countries around the world based on the weekly epidemiological update by the who . the who's current estimate of the global case fatality rate for covid-19 is 2.2%. however, the case fatality rate is affected by factors that include age, underlying preexisting conditions, and severity of illness and significantly varies between countries. the common clinical features of covid-19 pneumonia in adults include fever, dry cough, sore throat, headache, fatigue, myalgia and breathlessness . the disease manifestations in the infected patients range from mild pneumonia (81%) to moderate pneumonia (hypoxia requiring hospitalization, 14%), and critical illness (leading to invasive mechanical ventilation, multiorgan dysfunction and possibly death, 5%). the risk of death depends on age, underlying comorbidities and severity of the disease, increasing up to 49% in critically ill patients.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old 2. patients with covid-19 pneumonia confirmed by: reverse transcription polymerase chain reaction or pattern of covid-19 in computed tomography (ct) scan ( ground-glass opacity indicative of pneumonia on ct, opinion on consolidation, etc) with laboratory investigations exclusion criteria: 1. patients not confirmed to be covid-19 with pcr or radiologically. 2. patients who are diagnosed as bacterial pneumonia.